Abstracts Archive - Page 293 of 2607 - ACR Meeting Abstracts

Abstract Number: 1080 • ACR Convergence 2024
Electronic Consults to Rheumatology: A One-Year Analysis of Referral Outcomes and Trends in Access
Jeanne Gosselin¹, Brendan Thoms², Bonita Libman³, Tessalyn Morrison³, George McLane² and Teresa Fama⁴, ¹University of Vermont Medical Center, Waterbury, VT, ²University of Vermont Medical Center, South Burlington, VT, ³University of Vermont Medical Center, Burlington, VT, ⁴Univ of Vermont Health Network-Central Vermont Medical Center, Jericho, VT

Background/Purpose: Access to rheumatologic care is severely limited at our academic medical center with wait times of 9 months or longer for routine new patient…
Abstract Number: 1337 • ACR Convergence 2024
Gender and Ethnic Differences (or Lack Thereof) in Perceived Disease Burden in RA
Ali Malik¹, Dennis Ang¹, Adam Hall¹, John Herion¹ and Rupak Thapa², ¹Wake Forest University, Winston Salem, NC, ²Assistant Professor, Winston Salem, NC
Background/Purpose: Gender and ethnic disparities in health care are well reported in the general medical literature. Differences in symptom reporting or perceived health status can…
Abstract Number: 1602 • ACR Convergence 2024
Complications in Eosinophilic Granulomatosis with Polyangiitis (EGPA) Patients: A Nationwide Analysis
Faria Sami¹, Ahmad Basharat², Shahzad Ahmed Sami³ and Saman Tanveer⁴, ¹University of Alabama, Chicago, IL, ²Marshfield Clinic Health System, Marshfeild, WI, ³Trinity Health Oakland Hospital, Pontiac, ⁴John H. Stroger Jr. Hospital of Cook County, Chicago, IL
Background/Purpose: Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare autoimmune vasculitis of small to medium blood vessels, often causing multisystemic complications leading to increased morbidity and…
Abstract Number: 1551 • ACR Convergence 2024
Efficacy of Belimumab on Different Phenotypes of Joint and Skin Manifestations of Systemic Lupus Erythematosus: Preliminary Data from a Multicenter, Nationwide, Cohort of Patients: The BElimumab in Real Life Setting Study-New Joint and Skin (BeRLISS-NeJS)
Luca Iaccarino¹, Marisol Bracalenti², Alberto Cauli³, Lorenzo Cavagna⁴, Rossella De Angelis⁵, Roberto Depascale², Giacomo Emmi⁶, Roberto Gerli⁷, Marcello Govoni⁸, Alberto Lo Gullo⁹, Simone Negrini¹⁰, Luca Quartuccio¹¹, Maurizio Rossini¹², Carlo Salvarani¹³, Paola Tomietto¹⁴, Angelo Vacca¹⁵, Margherita Zen¹⁶ and doria Andrea², ¹University of Padua, PADOVA, Italy, ²University of Padova, Padova, Italy, ³University of Cagliari, Cagliari, Italy, ⁴University of Pavia and Fondazione IRCCS Policlinico San Matteo Hospital of Pavia, Pavia, Pavia, Italy, ⁵Università Politecnica delle Marche, Ancona, Italy, ⁶University of Trieste, Trieste, Italy, ⁷University of Perugia, Perugia, Italy, ⁸Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S.Anna, Ferrara, Italy, Ferrara, Italy, ⁹Rheumatology Unit, Papardo Hospital, Messina, Italy, ¹⁰University of Genova, Genova, Italy, ¹¹Division of Rheumatology, Department of Medicine (DMED), University of Udine, Udine, Italy, Udine, Italy, ¹²Rheumatology Unit, University of Verona, Verona, Italy, ¹³Azienda USL-IRCCS di Reggio Emilia and University of Modena and Reggio Emilia, Reggio Emilia, Italy, Reggio Emilia, Italy, ¹⁴Azienda Sanitaria Universitaria Giuliano Isontina, trieste, Italy, ¹⁵University of Bari, Bari, Italy, ¹⁶University of Padova, Padova, Padua, Italy
Background/Purpose: To evaluate the efficacy of belimumab on different skin and joint manifestations of the disease in a multicenter, nationwide, cohort (BeRLISS-NeJS) of patients with…
Abstract Number: 1583 • ACR Convergence 2024
The Association of Weakpositive Anti-RNA Polymerase III Antibodies with the Diagnosis and Complications of Systemic Sclerosis and Other Systemic Autoimmune Diseases
Mashood Badshah¹, Warren Balaja², Brannon Donovan³, Paul Schmidt³ and Megan Krause⁴, ¹The University of Kansas Medical Center, Kansas City, KS, ²University of Kansas Medical Center, Kansas City, KS, ³University of Kansas Medical Center, Kansas City, ⁴University of Kansas, Kansas City, KS
Background/Purpose: Anti-RNA polymerase III antibody (ARA) is associated with systemic sclerosis (SSc). The presence of ARA in patients with SSc is associated with the risk…
Abstract Number: 1598 • ACR Convergence 2024
Projecting the Impact of Standard, Reduced-Dose, and Minimal-Dose Glucocorticoid Regimens in the Treatment of ANCA-Associated Vasculitis Using Simulation Modeling
Naomi Patel¹, Aaron Wu¹, Shruthi Srivatsan¹, Eli Miloslavsky², Peter Merkel³, John Stone⁴, Hyon K. Choi⁵, Emily Hyle¹ and Zachary Wallace², ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Newton, MA, ³University of Pennsylvania, Philadelphia, PA, ⁴Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁵Massachusetts General Hospital, Lexington, MA
Background/Purpose: Glucocorticoids (GCs) remain a cornerstone of treatment of ANCA-associated vasculitis (AAV) but predispose people to infectious, metabolic, and other toxicities. We projected the long-term…
Abstract Number: 1488 • ACR Convergence 2024
Clinical Utility and Performance of Anti-C1q Antibodies for Systemic Lupus Erythematosus: Comparative Analysis of Three Different Assays
Mariana Gonzalez-Trevino¹, MeLea Hetrick¹, Alain Sanchez-Rodriguez², Ali Duarte-Garcia¹ and Anne Tebo³, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic College of Medicine and Science, Rochester, MN, ³Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
Background/Purpose: SLE is an autoimmune disorder characterized by autoantibody-mediated tissue damage. Antibodies against C1q (anti-C1q) can identify patients with LN and rising titers predict renal…
Abstract Number: 1562 • ACR Convergence 2024
Autoantibody Associations with Disease Manifestations in Patients with Early Diffuse Cutaneous Systemic Sclerosis: The Prospective Registry of Early Systemic Sclerosis
Aradhna Agarwal¹, Dahlia Hassan², Suiyuan Huang³, Flavia Castelino⁴, Shervin Assassi⁵, Robyn Domsic⁶, Tracy Frech⁷, Jessica Gordon⁸, Faye Hant⁹, Monique Hinchcliff¹⁰, Ami Shah¹¹, Victoria Shanmugam¹², Virginia Steen¹³, Dinesh Khanna³ and Elana Bernstein¹⁴, ¹Columbia University, New York, NY, ²Hospital for Special Surgery, New York, NY, ³University of Michigan, Ann Arbor, MI, ⁴Massachusetts General Hospital, Boston, MA, ⁵UTHealth Houston Division of Rheumatology, Houston, TX, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁷Vanderbilt University Medical Center, Nashville, TN, ⁸Division of Rheumatology, Weill Cornell Medical College, New York, NY, ⁹Medical University of South Carolina, Charleston, SC, ¹⁰Yale School of Medicine, Westport, CT, ¹¹Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ¹²NIH Office of Autoimmune Disease Research in the Office of Research on Women's Health, National Institutes of Health, Bethesda, MD, Bethesda, MD, ¹³Georgetown University School of Medicine, Washington, DC, ¹⁴Columbia University Irving Medical Center, New York, NY
Background/Purpose: Several autoantibodies have been linked to various disease manifestations of systemic sclerosis (SSc). Anti-RNA polymerase 3 (ARA) and anti-topoisomerase-I (ATA) are both associated with…
Abstract Number: 1468 • ACR Convergence 2024
Efficacy of bDMARDs in Early versus Established Disease in Axial Spondyloarthritis: A Meta-Analysis of Randomized Trials
Diego Benavent¹, Victoria Navarro Compán², Dafne Capelusnik³ and Sofia Ramiro⁴, ¹Rheumatology Department, Hospital Universitari de Bellvitge, Barcelona, Spain, CAMBRILS, Spain, ²La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, ³Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ⁴Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: The ASAS consensus definition of ‘early axial spondyloarthritis (axSpA)’ (axial symptoms ≤ 2 years) was expert-based given the scarcity of evidence1. We conducted a…
Abstract Number: 1594 • ACR Convergence 2024
Response to Mepolizumab Therapy in a Single-center Cohort of Eosinophilic Granulomatosis with Polyangiitis Patients: Characterization of Cytokine/Chemokine Pattern and Phenotypic Stratification
Michele Moretti¹, Francesco Ferro², Irene Martelli³, Francesca Pistone³, Giulia Greco³, Federica Di Cianni⁴, Nazzareno Italiano⁵, ROSARIA TALARICO⁴, Veronica Seccia⁶, Chiara Baldini⁷, Ilaria Puxeddu³ and Marta Mosca⁷, ¹University of Pisa, Pisa, Pisa, Italy, ²Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ³Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ⁴University of Pisa, Pisa, Italy, ⁵University of Pisa, Rovigo, Italy, ⁶Azienda Ospedaliero Universitaria Pisana, University of Pisa, Pisa, Italy, ⁷University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy
Background/Purpose: The introduction of Mepolizumab treatment has revolutionized the therapy of EGPA and has promoted the search for biomarkers predictive of response to treatment. However,…
Abstract Number: 1484 • ACR Convergence 2024
A Retrospective Evaluation of Glucagon-like Peptide-1 Receptor Agonists in SLE Patients
Philip Carlucci¹, Brooke Cohen², Amit Saxena³, H Michael Belmont³, Mala Masson⁴, Heather Gold⁵, Jill Buyon² and Peter Izmirly⁶, ¹New York University School of Medicine, New York, NY, ²NYU Grossman School of Medicine, New York, NY, ³NYU School of Medicine, New York, NY, ⁴NYU Langone Health, New York, NY, ⁵NYU Langone Health, NYC, ⁶New York University Grossman School of Medicine, New York, NY
Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP1-RA) are an emerging class of medications that significantly improve cardiometabolic outcomes. Whether these drugs may be useful in mitigating…
Abstract Number: 1596 • ACR Convergence 2024
Efficacy of Eosinophil-Targeting Therapies According to Disease Severity in Patients with Eosinophilic Granulomatosis with Polyangiitis
Bernhard Hellmich¹, Peter Merkel², David Jayne³, Benjamin Terrier⁴, Florence Roufosse⁵, Parameswaran Nair⁶, Nader Khalidi⁶, David J. Jackson⁷, Shunsuke Furuta⁸, Lena Börjesson Sjö⁹, Sofia Necander⁹, Anat Shavit¹⁰, Claire Walton¹¹ and Michael Wechsler¹², ¹Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, ²University of Pennsylvania, Philadelphia, PA, ³University of Cambridge, Cambridge, United Kingdom, ⁴Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ⁵Department of Internal Medicine, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium, ⁶McMaster University and St Joseph’s Healthcare, Hamilton, ON, Canada, ⁷Guy’s Severe Asthma Centre, Guy’s and St Thomas’ NHS Trust; School of Immunology and Microbial Sciences, King’s College London, London, United Kingdom, ⁸Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan, ⁹Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ¹⁰BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ¹¹Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹²National Jewish Health, Denver, CO
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterized by asthma, eosinophilia, and small-to-medium size vessel vasculitis, with individual manifestations widely ranging…
Abstract Number: 1563 • ACR Convergence 2024
Prevalence, Risk Factors and Associations for Osteoporosis in Postmenopausal Women with Scleroderma
Gayane Matusov¹, Jon Giles² and Francesco Boin³, ¹Scripps Clinic, San Diego, CA, ²Cedars Sinai Medical Center, Los Angeles, CA, ³Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Case-control studies have shown that systemic sclerosis (SSc) patients exhibit higher prevalence of osteoporosis (OP) compared to subjects in the general population. The pathophysiology…
Abstract Number: 1499 • ACR Convergence 2024
Outcome of Newly Onset SLE with Neuropsychiatric Symptoms and Its Clinical Features in Daily Clinical Practice: A Single Center Study
Shuzo Sato, Fumitaka Seike, Yuya Sumichika, Kenji Saito, Shuhei Yoshida, Haruki Matsumoto, Jumpei Temmoku, Yuya Fujita, Naoki Matsuoka and Tomoyuki Asano, Fukushima Medical University, Fukushima, Fukushima, Japan
Background/Purpose: Although neuropsychiatric (NP) symptoms may occur in patients with SLE even in initial onset, studies regarding the distinct clinical features of SLE patients with…
Abstract Number: 0552 • ACR Convergence 2024
Presence of MAIT Cells in Synovial Tissue of Patients with Axial Spondyloarthritis: A Comparative Study
Andre Ramon¹, Philippe Saas², Charline Vauchy³, Maxime Samson² and ERIC TOUSSIROT⁴, ¹Dijon University Hospital, Besançon, France, ²Franche-Comté University, EFS, INSERM, UMR RIGHT, Besançon, France, Besançon, France, ³INSERM CIC-1431, CHU de Besançon, Besancon, France, Besançon, France, ⁴university hospital of BESANCON, besancon, France
Background/Purpose: Mucosal-associated invariant T (MAIT) cells are innate immune T cells that are located at the mucosal barriers. They play a role in mucosal defense,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].